This clinical trial assesses the change in lymphatic structure from placement of an intravenous (IV) line and fluid administration using a diagnostic agent, indocyanine green (ICG), with SPY (Trademark) angiography in breast cancer patients at risk for breast cancer-related lymphedema (BCRL). Patients that are diagnosed with breast cancer with lymph node involvement often undergo treatment that includes surgery to remove the axillary nodes and radiation. Unfortunately, this procedure increases the incidence of BCRL in the surgical arm, as well as other problems including heaviness of the arm, fibrotic skin changes, and an increase in infection risk. Because of these symptoms, venipuncture (blood draw) is often avoided in these arms. Researchers want to show that placement of an IV line and fluid administration in patients at risk for BCRL will indeed not alter the lymphatic structure of the arm and will not change the incidence of BCRL by administering indocyanine green (ICG) dye to patients and assessing their arm lymphatics. ICG is a fluorescent dye that is able to be visualized by the SPY angiography imaging system as it travels through the lymphatic system, allowing researchers to assess how well blood flows throughout the body. Receiving ICG and undergoing SPY angiography may be effective in showing that placement of an IV and fluid administration in breast cancer patients at risk for BCRL will not alter the lymphatic structure of their arm and will not change the incidence of BCRL.

Start Date14 Aug 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT05038098 / Not yet recruitingPhase 1IIT

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial

This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.

Start Date31 Mar 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

ISRCTN26150156 / RecruitingPhase 2IIT

Indocyanine Green and near-infrared fLuorescence in paediatric Oncology surgery (GLO-Surgery)

Start Date06 Jan 2025

Sponsor / Collaborator

University of Birmingham

100 Clinical Results associated with Indocyanine Green

100 Translational Medicine associated with Indocyanine Green

100 Patents (Medical) associated with Indocyanine Green

4,695

Literatures (Medical) associated with Indocyanine Green

01 Mar 2025·Biomaterials

Tertiary lymphoid structure formation induced by LIGHT-engineered and photosensitive nanoparticles-decorated bacteria enhances immune response against colorectal cancer

Article

Author: Hu, Lijun ; Su, Zhongzhen ; Jiang, Yujie ; Shuai, Xintao ; Li, Tan ; Deng, Shaohui ; Chen, Hui ; Chen, Qiu ; Gao, Honglin ; Xiao, Zecong

Tertiary lymphoid structures (TLSs) are known to enhance the prognosis of patients with colorectal cancer (CRC) by fostering an immunologically active tumor microenvironment (TME). Inducing TLS formation therapeutically holds promise for treating immunologically cold CRC, though it poses technical challenges. Here, we design and fabricate a photosensitive bacterial system named E@L-P/ICG. This system is engineered bacteria internally loaded with the cytokine LIGHT and surface-modified with PLGA/ICG nanoparticles (P/ICG NPs). Once accumulated in orthotopic colonic tumors in mice, E@L-P/ICG generates a mild photothermal effect under laser irradiation due to the photosensitive P/ICG NPs. This photothermal effect triggers the self-rupture of E@L-P/ICG and the death of surrounding tumor cells to release adjuvants and antigens, respectively, which in turn synergistically activate the adaptive immune responses. Furthermore, the cytokine LIGHT released from ruptured E@L-P/ICG stimulates the generation of high endothelial vessels (HEVs), promoting lymphocyte recruitment within the TME. These mechanisms lead to the TLS formation in CRC, which further boosts adaptive immune responses through effective infiltration of T cells and B cells, resulting in effectively inhibited tumor growth and extended survival of mice. Our study shows the potential of the E@L-P/ICG system in photosensitively inducing the TLS formation to treat CRC in clinic.

01 Mar 2025·Biomaterials

Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics

Article

Author: Jiang, Yuke ; Shi, Guangwei ; Zhong, Xiaoru ; Li, Zhijie ; Long, Ying ; Huang, Zhenhui ; Yang, Runwei ; Dong, Zhiyu ; Li, Jiexuan ; Wang, Jigang ; Bai, Chongzhi ; Jia, Lin ; Zheng, Liuhai ; Chen, Chunbo ; Wang, Huifang ; Wei, Jinxi ; Dai, Lingyun

Targeted therapies have revolutionized traditional cancer treatments by precisely targeting tumor cells, enhancing efficacy and safety. Despite this advancement, the proportion of cancer patients eligible for such therapies remains low due to the absence of suitable targets. Here, we investigate whether the translocation of the immunogenic cell death (ICD) marker calreticulin (CALR) from the endoplasmic reticulum (ER) to the cell surface following ICD induction can serve as a target for targeted therapies. To target CALR, a nanobody Nb215 identified from a naïve VHH phage library with high binding affinity to both human and mouse CALR was employed to engineer probiotic EcN 1917. Our results demonstrated that CALR nanobody-modified EcN-215 coupled with the photothermal dye indocyanine green (ICG) was able to exert NIR-II imaging-guide photothermal therapy (PTT). Moreover, PTT with EcN-215/ICG can reshape the tumor microenvironment by enhancing the infiltration of CD45⁺CD3⁺ T cells and CD11b⁺F4/80⁺ macrophages. Furthermore, the antitumor activity of CALR-targeted EcN-215/ICG is synergistically enhanced by blocking CD47-SIRPα axis. Collectively, our study provides a proof of concept for CALR-targeted therapy. Given that CALR translocation can be induced by various anticancer therapies across numerous tumor cell lines, CALR-targeted therapies hold promise as a novel approach for treating multiple types of cancers.

01 Feb 2025·Journal of Colloid and Interface Science

Nuclear-targeted smart nanoplatforms featuring double-shell hollow mesoporous copper sulfide coated with manganese dioxide synergistically potentiate chemotherapy and immunotherapy in hepatocellular carcinoma cells

Article

Author: Zhao, Mei-Xia ; Li, Lin-Song ; Chen, Peng-Wei ; Tang, Xian-Jiao ; Cheng, Dong ; Zhao, Xue-Jie ; Zhu, Wen-Qi ; Liu, Bang-Bang ; Yang, Xiaojing

Smart nanoplatforms designed for nuclear-targeted delivery of chemotherapeutic agents to tumor sites are pivotal in advancing tumor treatment and immunotherapy. Herein, we introduced a novel nuclear-targeting double-shell smart nanoplatform (HMCuS/Pt/ICG@MnO₂@9R-P201 (HMCPIM9P)), which synergistically enhances chemotherapy, photodynamic therapy (PDT), photothermal therapy (PTT), immunotherapy and chemodynamic therapy (CDT). The core of this nanoplatform consists of double-shell multifunctional nanoparticles (HMCuS@MnO₂) that enable targeted delivery of the photosensitizer Indocyanine Green (ICG) and the chemotherapeutic agent cisplatin (Pt). By effectively consuming glutathione (GSH), these nanoparticles boost the chemotherapeutic efficacy of Pt. Additionally, the manganese ion (Mn²⁺) present activate the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) (cGAS-STING) pathway, bolstering adaptive immune responses against tumors and elevating the level of tumor-infiltrating CD8+ T cells. The incorporation of the hepatoma-targeting peptide (9R-P201 peptide) allows the system to exhibit FOXM1 receptor-mediated nuclear targeting properties specifically in hepatocellular carcinoma (HCC). Notably, when combined with near-infrared (NIR) light, HMCPIM9P demonstrated a remarkable tumor inhibition rate of 95.6 %, fostered a robust immune response, and significantly inhibited tumor growth and recurrence. Overall, the smart nanoplatform boasts active nuclear targeting capabilities, enabling the enrichment of chemotherapeutic agents at tumor sites, and holds great potential for synergistic applications in enhancing chemotherapy and immunotherapy for HCC.

News (Medical) associated with Indocyanine Green

13 Nov 2024

·www.businesswire.com

Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery

MINNEAPOLIS--( BUSINESS WIRE )-- Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company’s Phase 2, multi-center VISUALIZE trial, evaluating the efficacy and safety of abenacianine for injection (VGT-309) in patients with cancer in the lung. Abenacianine for injection is a novel, investigational tumor-targeted fluorescent imaging agent designed to improve the visibility of difficult-to-find and previously undetected tumors during minimally invasive and robotic-assisted surgical procedures. “The VISUALIZE trial will provide additional, valuable insights illuminating the potential of our novel imaging agent to address existing deficits in tumor visualization during lung surgery,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience. “Completing enrollment in the trial is an exciting milestone that reflects our team’s dedication, as well as the commitment of the VISUALIZE clinical investigators and study participants. We look forward to sharing the results of this study.” Data from previous clinical studies of abenacianine for injection suggest the agent allowed surgeons to see tumor tissue during minimally invasive surgery (MIS), including robotic-assisted surgical procedures, providing “molecular sight” and potentially increasing their confidence in MIS. For the Phase 2 VISUALIZE trial, investigators at six sites in the United States and Australia enrolled 89 patients with cancer in the lung, all of whom received 0.32mg/kg abenacianine for injection as a short infusion 12 to 36 hours prior to surgery. Following data readout from the VISUALIZE trial, Vergent intends to advance the agent into a Phase 3 study. Assuming positive Phase 3 results, the company will file a new drug application (NDA) for abenacianine for injection for cancer in the lung. About Lung Cancer Surgery Approximately 25% of all U.S. lung cancer patients undergo lung cancer surgery, which can be a curative treatment if lung cancer is diagnosed early, and all tumor tissue is removed. 1 MIS and robotic-assisted surgery methods are increasingly utilized in lung cancer resection because these approaches are associated with shorter hospital stays, smaller incisions, less blood less, and decreased post-operative complications. While these are important advantages, MIS and robotic-assisted surgery often compromise surgeons’ sight and ability to feel tissue during procedures, making it difficult for them to distinguish tumors from normal tissue and ensure all tumor tissue is removed. About the VISUALIZE Clinical Trial The Phase 2, multi-center, open-label VISUALIZE study ( NCT06145048 ) was designed to evaluate the efficacy and safety of abenacianine for injection in patients undergoing surgery for proven or suspected cancer in the lung. Each of the 89 patients in the study received 0.32mg/kg abenacianine for injection 12 to 36 hours prior to surgery. Following an attempt to identify each tumor using standard surgical techniques, investigators used a commercially available near-infrared (NIR) endoscope to assess the presence of tumor tissue, which was then confirmed by pathology. Primary efficacy endpoints included visualization of tumors intraoperatively, surgical margin assessment, and identification of additional cancers or positive lymph nodes that may not have been seen preoperatively. About Abenacianine for Injection (VGT-309) Abenacianine for injection is a tumor-targeted fluorescent imaging agent designed to enable a complete solution for optimal tumor visualization during open, minimally invasive and robotic-assisted surgical procedures. Abenacianine for injection is delivered to patients via a short intravenous infusion several hours before surgery. Invented in Professor Matt Bogyo’s Lab at Stanford University School of Medicine, the molecule binds tightly (i.e., covalently) to cathepsins, a family of proteases that are overexpressed across a broad range of solid tumors. This approach, if successful, would provide distinct clinical advantages and position abenacianine for injection as an ideal tumor imaging agent. Abenacianine for injection’s imaging component is the near infrared (NIR) dye indocyanine green (ICG), which is compatible with all commercially available NIR intraoperative imaging systems that support MIS technologies and is a preferred dye to minimize confounding background autofluorescence. About Vergent Bioscience, Inc. Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergent’s lead compound, abenacianine for injection, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see difficult-to-find or previously undetected tumors in real-time during surgery, so that they can ensure all tumor tissue is removed. The company is first evaluating abenacianine for injection for cancer in the lung, with the potential to expand its application to a wide range of solid tumors. Vergent Bioscience is a privately held company based in Minneapolis, MN. Lu T, et al. "Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades," Cancer Manag Res. 2019 Jan 21;11:943-953. https://pubmed.ncbi.nlm.nih.gov/30718965/

Phase 2Clinical ResultPhase 3

18 Jul 2024

·www.businesswire.com

Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery

MINNEAPOLIS--( BUSINESS WIRE )-- Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that data published in The Annals of Thoracic Surgery reinforce the clinical potential of VGT-309, the company’s investigational intraoperative molecular imaging (IMI) agent, to help surgeons see difficult-to-find and previously undetected tumors in the lung during surgery. The findings support previous clinical trial results suggesting that VGT-309 could help ensure all tumor tissue is removed during minimally invasive and robotic-assisted surgical procedures. “The expanded use of minimally invasive surgery, including robotic-assisted technologies, for lung cancer has created a significant and growing need for better visualization during these surgeries, which can be curative when lung cancer is diagnosed early enough and all tumor tissue is removed,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience. “We are pleased that data from our clinical program continue to suggest VGT-309 may help overcome existing challenges to tumor visualization and thereby optimize surgical outcomes for physicians and patients.” The Phase 2* efficacy study evaluated the frequency that IMI with VGT-309 improved surgical outcomes in 40 individuals with suspected or proven cancer in the lung who were eligible for surgery. The primary efficacy endpoint was the proportion of patients with at least one clinically significant event. Clinically significant events were defined as localization of lesions not found by standard surgical techniques, identification of synchronous and occult cancers, and identification of inadequate surgical margin. Each patient in the study received VGT-309 preoperatively through intravenous infusion. Following an attempt to localize the target lesion using standard surgical techniques, investigators used a commercially available near infrared (NIR) endoscope to visualize the lesion, which was then assessed by pathology. Of the 40 participants administered VGT-309 who underwent the standard-of-care surgical resection for suspected lung cancer, 17 (42.5%) had at least one clinically significant event. VGT-309 with NIR fluorescence imaging visualized a range of primary and metastatic tumor types intraoperatively, including adenocarcinoma in situ, invasive adenocarcinoma, lymphoma, colorectal cancer, neuroendocrine tumors, sarcomas, and squamous cell carcinoma. VGT-309 appeared safe and well tolerated in this study, with no infusion reactions and no drug-related serious adverse events. “While the prevalence of minimally invasive surgery has increased over the years, these surgical approaches require surgeons to work in a small area with a restricted view and limited tactile clues, increasing the possibility that tumor tissue will be difficult to locate or even missed,” said study investigator and senior author Sunil Singhal, M.D., chief of the Division of Thoracic Surgery in the Perelman School of Medicine at University of Pennsylvania. “The study findings published today in The Annals of Thoracic Surgery add to the growing body of evidence suggesting that VGT-309 has the potential to provide meaningful benefit to both surgeons and cancer patients during minimally invasive surgery.” To further evaluate the efficacy of VGT-309, Vergent is currently conducting the Phase 2 multicenter VISUALIZE study ( NCT06145048) . Investigators at six sites in the United States and Australia plan to enroll 100 patients in this Phase 2 study, which Vergent expects to complete by the end of 2024. *This clinical trial ( ClinicalTrials.gov Identifier: NCT05400226) was supported by the National Cancer Institute of the National Institutes of Health under award number R44CA277890. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About VGT-309 VGT-309 is a tumor-targeted fluorescent imaging agent designed to enable a complete solution for optimal tumor visualization during open, minimally invasive and robotic-assisted surgical procedures. VGT-309 is delivered to patients via a short intravenous infusion several hours before surgery. Invented in Professor Matt Bogyo’s Lab at Stanford University School of Medicine, the molecule binds tightly (i.e., covalently) to cathepsins, a family of proteases that are overexpressed across a broad range of solid tumors. This approach, if successful, provides distinct clinical advantages and positions VGT-309 as an ideal tumor imaging agent. VGT-309’s imaging component is the near infrared (NIR) dye indocyanine green (ICG), which is compatible with all commercially available NIR intraoperative imaging systems that support MIS technologies and is a preferred dye to minimize confounding background autofluorescence. About Vergent Bioscience, Inc. Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent designed to enable surgeons to see difficult-to-find or previously undetected tumors in real-time during surgery, so that they can ensure all tumor tissue is removed. The company is first evaluating VGT-309 for cancer in the lung, with the potential to expand its application to a wide range of solid tumors. Vergent Bioscience is a privately held company based in Minneapolis, MN.

Clinical ResultPhase 2

12 Feb 2024

·www.fiercebiotech.com

CMR Surgical adds new tissue imaging tech to Versius robot

CMR Surgical's vLimeLite system will first be installed at Gloucestershire Royal Hospitals NHS Trust in the U.K. for use in upper gastrointestinal surgery procedures. CMR Surgical is launching a new imaging technology to help users of its Versius robot visualize the flow of blood through organs during a procedure. The company’s vLimeLite add-on incorporates a near-infrared fluorescent light that reacts with the injectable medical dye indocyanine green, known as ICG. The CE-marked system aims to highlight blood vessels and tissue perfusion beyond the naked eye, as well as the body’s bile duct anatomy. “This is the most significant update of Versius since it launched back in 2019,” CEO Supratim Bose said in the company’s announcement. “We have listened to the needs of surgeons, and I’m delighted that we have been able to give them what they want—a best-in-class ICG product that we know will make a real difference for their patients.” The system will first be installed at Gloucestershire Royal Hospitals NHS Trust in the U.K. for use in upper gastrointestinal surgery procedures. CMR said it plans to roll out vLimeLite first in the U.K., Ireland and Hong Kong before obtaining additional regulatory approvals and expanding globally over the course of this year. vLimeLite will launch with video overlays that integrate with Versius’ 3D vision and will allow the surgeon to toggle between green, cyan and grayscale ICG viewing modes. “I think what is really special is the overlay mode option, which means Versius surgeons will be able to use our integrated ICG system while continuing to view in full color with the same video quality,” said Mark Slack, CMR co-founder and chief medical officer. “vLimeLite truly allows surgeons to see what was once invisible to them.” In January, CMR reported what it described as its strongest quarter on record, in terms of system placements and procedures performed. Over the course of the full 12 months of 2023, the company said its install base grew 50% over 2022’s tally, with surgery counts growing more than 60% to a total of more than 17,000 since Versius’ launch. The numbers follow expansions in Europe, Asia, the Middle East, Africa and Latin America. The company also said it plans to launch new instrumentation options and digital software for Versius in 2024. Late last year, CMR opened a new manufacturing facility near its home in Cambridge, U.K., that it says has the capacity to produce up to 500 Versius systems per year.

100 Deals associated with Indocyanine Green

External Link

KEGG	Wiki	ATC	Drug Bank
D01342	Indocyanine Green	V04CX01	DB09374

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bile Duct Diseases	US	Novadaq Technologies ULC	21 Nov 2018
Uterine Cervical Cancer	US	Novadaq Technologies ULC	21 Nov 2018
Vascular Diseases	US	Novadaq Technologies ULC	21 Nov 2018
Breast Cancer	JP	Daiichi Sankyo Co., Ltd.	18 Sep 2009
Melanoma	JP	Daiichi Sankyo Co., Ltd.	18 Sep 2009
Contrast agents	JP	Santen Pharmaceutical Co., Ltd.	11 Apr 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 2	US	University of Pennsylvania	14 Aug 2024
Head and Neck Neoplasms	Phase 2	US	Tactile Systems Technology, Inc.	01 Oct 2016
liver function failure	Phase 2	US	CardioX, Inc.	01 Nov 2015
Central Nervous System Neoplasms	Phase 2	US	Abramson Cancer Center	10 Jun 2015
Brain Cancer	Preclinical	-	University of Pennsylvania	01 Jun 2015
Breast Ductal Carcinoma	Preclinical	US	Abramson Cancer Center	01 Jul 2011
Lobular Carcinoma	Preclinical	US	Abramson Cancer Center	01 Jul 2011
Lung Cancer	Preclinical	US	University of Pennsylvania	01 May 2011
Solitary Pulmonary Nodule	Preclinical	US	University of Pennsylvania	01 May 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2024	Not Applicable	Retinoblastoma	-	Indocyanine Green (TTT alone)	vicgeggotw(xiexprojau) = medkkiyzar chtypswwkr (rtvmjjnbmr )	Positive	19 Sep 2024
EURETINA2024	Not Applicable	Retinoblastoma	-	Indocyanine Green (ICG enhanced TTT)	qrehprneeo(heryvnzfvc) = vugakqfozu jgucxdjmgr (zkkdvjmcak ) View more	Positive	19 Sep 2024
WCLC2024	Not Applicable	Bronchopneumonia	-	Indocyanine Green (Mesh nebulizer)	(eawfciwsez) = no adverse events were recorded lpuvcbpvgu (gmxjxmvyre ) View more	-	07 Sep 2024
NCT01034670 (CTgov)	Not Applicable	Gastrointestinal Stromal Tumors \| Stomach Cancer	3	fluorescent Peptide+indocyanine green	bejkcnnczk(zbwqzmcgnn) = ycffknbfrp stmugkxrgp (ywhxfrytys, shxfxodvay - kxxpfxchbd) View more	-	26 Jun 2024
NCT05094102 (CTgov)	Not Applicable	Breast Cancer \| Lymphedema	9	OnLume Imaging System+Indocyanine green	diohwsfjxy(jwysmjyioz) = cbhfzlvbtj jgyllypytm (cvopsdbrqq, knogwlwfnh - qyiyfqlqph) View more	-	23 May 2024
AHNS2024	Not Applicable	-	-	ICG injection	bddkxmqltx(twulyhreir) = fcmboikimr vaovnktpqx (fvuxrdacky, 63.1 - 100) View more	-	15 May 2024
MP61-16 (AUA2024)	Not Applicable	Squamous Cell Carcinoma of the Penis	12	Indocyanine Green	lkrkqkhedl(hbdnzbukkh) = Postoperative complications were recorded in 8 out of 16 procedures, with a low rate of wound dehiscence and no flap necrosis observed kyongsfjqc (jpjgmvtzkw )	Positive	01 May 2024
MP61-16 (AUA2024)	Not Applicable	Squamous Cell Carcinoma of the Penis	12	Indocyanine Green		Positive	01 May 2024
902 (ESGO2024)	Not Applicable	Endometrial Carcinoma	22	Indocyanine green (ICG)	xpjlklzcom(xcczuhrhgd) = There were no allergic reactions to the ICG numlxiqoiu (lcixsuevqj )	Positive	10 Mar 2024
ESMO2023	Not Applicable	Breast Cancer	69	indocyanine green (ICG and RI)	pqaywlgdpb(oiqfitvmhz) = kgcggcykwi vfsfkkrfvu (jgpcfoouae ) View more	-	21 Oct 2023
ESMO2023	Not Applicable	Breast Cancer	69	indocyanine green (Blue dye and RI)	rwmmcmuyxw(yejgfvjlni) = awwpinsyxo dehnvychvz (zhqlyalthv, 94.3 - 99.1)	-	21 Oct 2023
NCT04511026 (CTgov)	Phase 2	Endometrial Carcinoma	6	Single Photon Emission Computed Tomography (SPECT)+Lymphoseek+Indocyanine Green (ICG)	tdvazevjvh(ryeliwdlrx) = rhdvrecorv xdswriokxc (bslruyakez, ainvcbxrbo - fpermmnhem) View more	-	11 Oct 2023
NCT04084067 (Pubmed \| Pediatr Blood Cancer)	Phase 1	Solid tumor	12	Indocyanine green (ICG)	blsswqryet(skswlexzds) = ICG guidance failed to localize pulmonary metastases in five (42%) patients who had inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, or papillary thyroid carcinoma fmnhrrnojl (pppwrbmfuh )	Negative	01 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis